Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity Post author: Post published:December 1, 2023 Post category:uncategorized The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption. You Might Also Like Study highlights increase in VZV-induced CNS infections and dementia risk February 27, 2025 Study uncovers new weapon against PARP inhibitor-resistant ovarian cancers January 10, 2024 Early pregnancy vitamin D deficiency increases risk of preterm birth February 3, 2025